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During organ culture of intact vessels, endothelin receptors (ETRs) were upregulated in vascular smooth muscle cells (VSMCs) by
various stimuli, but whether inflammation alters ETR expression in vivo remains unclear. We aimed to explore the effects of
lipopolysaccharide (LPS) challenge on ETR expression in the VSMC in vivo. Male Sprague-Dawley rats received a single
intraperitoneal injection of LPS (5mg/kg body weight) or normal saline (NS) for 6 hrs. The function and expression of ETR type
A (ETA) and type B (ETB) were evaluated in the mesenteric arteries without endothelium, by using myograph system, real-time
quantitative PCR, Western blot, and immunohistochemical staining, respectively. Serum tumor necrosis factor-α (TNF-α) level
was assessed by using enzyme-linked immunosorbent assay. The results showed that, compared to control (NS) group, LPS
treatment potently enhanced the vasoconstriction mediated by ETA or ETB in rat mesenteric artery, with elevated maximum
effects. ETA and ETB expressions in the VSMC were increased at both mRNA and protein levels after LPS treatment, paralleled
with activation of the NF-κB pathway and augmented serum TNF-α level. Conclusively, in the rat model of immediate systemic
inflammation induced by LPS, ETA and ETB expressions were increased in the mesenteric arterial VSMC, paralleled with
enhanced receptor-mediated vasoconstriction and activation of the NF-κB pathway. Our data has for the first time
demonstrated the upregulation of ETRs in VSMCs by LPS-induced immediate inflammation in vivo.
1. Introduction
Vasospasm and vascular wall remodeling are important
functional/morphological disorders in the vascular wall.
Numerous stimuli target on vascular smooth muscle cells
(VSMCs) and alter vasomotion, being major pathological
factors in the progression of atherosclerotic vascular diseases.
In the vasculature, endothelin-1 (ET-1) is one of the most
potent endogenous vasoconstrictors, showing various biolog-
ical functions through binding to its receptors. Among the
subtypes of endothelin receptors (ETRs), endothelin type A
receptor (ETA) is expressed on VSMC, mediating vasocon-
striction and proliferation [1, 2], while endothelin type B
receptor (ETB) is normally expressed on vascular endothelial
cells (VECs), mediating vasodilatation of VSMC via nitric
oxide (NO) and prostacyclin I2 (PGI2) pathways [3]. Distinct
from such relaxing phenotype of ETB (termed ETB1), a
contractile phenotype of ETB (termed ETB2) was discov-
ered on VSMC, mediating vasoconstriction under certain
pathophysiological conditions. Abundant studies reported
aberrant elevation of ETRs, specifically upregulated ETA and
induced ETB2, in the VSMC in animal models and human
subjects with various cardiocerebrovascular diseases [4]. Aug-
mented expressions of ETA and ETB2 result in enhanced
vasoconstriction triggered by their endogenous ligand, ET-1,
and thus lead to modulated vascular tone and accelerated
proliferation of VSMC.
It has been well-documented that inflammation plays a
crucial role in the progression of cardiovascular diseases.
Dysregulation of serum proinflammatory cytokines elicits
deleterious effects to the VSMC via activation of intracellular
signals and therefore causes vascular dysfunction. Previously,
by using an in vitro organ culture model, we demonstrated
the upregulation of ETB2 expression in VSMC through
the activation of the nuclear factor-κB (NF-κB) pathway
after exposure of the arteries to tumor necrosis factor-α
(TNF-α), a key proinflammatory cytokine [5]. Additionally,
during organ culture, expressions of ETA and ETB2 were
enhanced by lipid-soluble smoking particles [6, 7] and low-
density lipoprotein (LDL) [8]. The above data, to some
aspect, indicated a link between upregulation of ETRs and
inflammation associated with cardiovascular risk factors.
Nevertheless, there is still a lack of in vivo data concerning
the altered expression of ETRs in mesenteric arterial VSMC
in an efficient animal model of inflammation. Intraperitoneal
administration of lipopolysaccharide (LPS) could increase
TNF-α production by peritoneal macrophages and is thus
widely employed as an animal model of immediate systemic
inflammation [9, 10]. To further verify the induction of ETRs
by inflammation in vivo, we herein established a classic rat
model of LPS-induced immediate systemic inflammation,
and the mesenteric arteries were used for the further study.
2. Materials and Methods
2.1. Animals and Tissue Preparation. Male Sprague-Dawley
rats (SPF, weighing about 200 g) were purchased from
Shanghai Center of Experimental Animals, Chinese Acad-
emy of Sciences (Shanghai, China). Rats had free access to
water and standard rat chow pellets and were housed under
controlled temperature (22 ± 1°C) and humidity (50-60%)
with a 12hr light-dark cycle from 7AM to 7PM. After
acclimatization for 1 week, thirty rats were randomly allo-
cated into two groups: normal saline (NS) and LPS, receiv-
ing a single intraperitoneal administration of equivalent
volume of NS or LPS (5mg/kg body weight), respectively.
LPS (Sigma-Aldrich, Saint Louis, MO, USA) was dissolved
in normal saline. Six hours after injection, rats were anes-
thetized with an intraperitoneal injection of pentobarbital
sodium (10mg/rat). The blood was drawn from carotid
arteries of rats using a catheter (24G), centrifuged at
2000 rpm for 15min within 30min of collection and stored
at -80°C until assayed. After blood collection, euthanasia of
rats was performed by decapitation. The mesenteric tissue
sample was gently removed from the abdomen. Dissection
of the mesenteric artery and denudation of the endothelium
with Triton X-100 were performed as described previously
[6]. All the animal experimental procedures were approved
by the Ethics Committee on Animal Research from The
First Affiliated Hospital of Xiamen University, complying
with Animal Research: Reporting of In Vivo Experiments
(ARRIVE) Guidelines, and were carried out in accordance
with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals (8th Edition) and American
Veterinary Medical Association (AMVA) Guidelines for the
Euthanasia of Animals (2013 Edition).
2.2. Functional Assay (Myograph). The arteries (without
endothelium) were cut into 1mm long cylindrical segments
and mounted to a myograph system (620M, Danish Myo
Technology A/S, Aarhus, Denmark) for recording the
receptor-mediated vasoconstriction. The concentration-
response curves (CRCs) were performed by cumulative
administration of selective ETB agonist sarafotoxin 6c
(S6c, Sigma-Aldrich, Saint Louis, MO, USA), followed by
nonselective ETR agonist ET-1 (Calbiochem, La Jolla,
CA, USA), as previously described [6, 11]. Briefly, after S6c
CRCs were obtained, the arterial rings were coincubated with
S6c (10-7.5M) for 30min. The desensitization of ETB was
verified by lack of response to further administration of S6c
(10-7M). The subsequent ET-1 CRCs represent ETA-medi-
ated vasoconstriction. This method is comparable to the
application of BQ-788, the selective ETB antagonist, for
assessment of ETA-mediated vasoconstriction [12]. S6c and
ET-1 were dissolved in bovine serum albumin solution
(0.1%, Sigma-Aldrich, Saint Louis, MO, USA).
2.3. RNA Extraction and Real-Time Quantitative Reverse
Transcription Polymerase Chain Reaction (QRT-PCR). The
arterial segments (without endothelium, 6mm in length)
were homogenized in Lysing Matrix D centrifuge tubes
(MP Biomedicals, Santa Ana, CA, USA), containing
extraction buffer obtained from RNeasy Mini Kit (Qiagen,
Hilden, Germany), in a FastPrep-24 5G homogenizer (MP
Biomedicals, Santa Ana, CA, USA). Total RNA was extracted
following the manufacturer’s instructions. Reverse transcrip-
tion of total RNA to cDNA was carried out with SuperScript
III First-Strand Synthesis System (Invitrogen, Carlsbad,
CA, USA) in a 2720 Thermal Cycler (Applied Biosystems,
Carlsbad, CA, USA) following the manufacturer’s instructions.
Real-time quantitative PCR was performed in a
QuantStudio 6 Flex Real-Time PCR system (Applied Bio-
systems, Carlsbad, CA, USA) with the reaction protocol
as described previously [6]. Primers were as follows: ETA
(Ednra, GenBank accession no. NM_012550) mRNA:
forward 5′-GCGTCGAGAGGTGGCAAA-3′ and reverse
5′-CCAGCACAGGGCGAAGAT-3′; ETB (Ednrb, GenBank
accession no. NM_017333) mRNA: forward 5′-GATACG
ACAACTTCCGCTCCA-3′ and reverse 5′-GTCCACGAT
GAGGACAATGAG-3′. Elongation factor-1 (EF-1, Eef1a1,
GenBank accession no. NM_175838) mRNA was used as
reference (internal control) [5, 11]. The primers were for-
ward 5′-GCAAGCCCATGTGTGTTGAA-3′ and reverse
5′-TGATGACACCCACAGCAACTG-3′. All the primers
were synthesized by Sangon Biotech (Shanghai, China). Rel-
ative expressions of ETR mRNA were analyzed with 2-ΔΔCt
method and normalized with EF-1 mRNA expression.
2.4. Hematoxylin-Eosin and Immunohistochemical Staining.
Paraformaldehyde-fixed and paraffin-embedded arterial seg-
ments (without endothelium, 6mm in length) sections were
used for hematoxylin-eosin and immunohistochemical
2 Mediators of Inflammation
staining. Briefly, after fixation with 4% neutral formaldehyde
and washed with running water and 75% ethanol. After
dehydrated and hyalinized in a TP1020 tissue processor
(Leica, Nussloch, Germany), tissues were then embedded by
a HistoCore Arcadia (Leica, Nussloch, Germany) and cut at
3.5μm thickness with an RM2245 semimotorized rotary
microtome (Leica, Nussloch, Germany). Dewaxing of the tis-
sues was performed with Van-Clear reagent (Huntz, Wuhan,
China) and gradient ethanol. Sections were then used for
downstream staining with hematoxylin-eosin or primary
antibodies. The following antibodies were used: rabbit poly-
clonal antibodies against ETA (ab117521, 1 : 2000, Abcam,
Cambridge, UK) and ETB (ab117529, 1 : 2000, Abcam, Cam-
bridge, UK) and horseradish peroxidase-conjugated goat
anti-rabbit secondary antibody (A16110, 1 : 200, Invitrogen
Carlsbad, CA, USA). Sections were then visualized with a
DAB kit (Maixin Biotech, Fuzhou, China), counterstained
with hematoxylin, and observed under an Echo Revolve
hybrid microscope (Echo Laboratories, San Diego, CA,
USA). No detectable staining was observed in all negative
control slides treated with nonimmune rabbit serum (10%)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). The
experiments were repeated 3 times independently.
2.5. Western Blot. Total protein was extracted from the arte-
rial segments (without endothelium, 9mm in length) in
Lysing Matrix D centrifuge tubes (MP Biomedicals, Santa
Ana, CA, USA), containing T-PER Tissue Protein Extraction
Reagent (Pierce, Rockford, IL, USA) supplemented with
Halt Protease and Phosphatase Inhibitor Cocktail (Pierce,
Rockford, IL, USA), in a FastPrep-24 5G homogenizer
(MP Biomedicals, Santa Ana, CA, USA). Protein concentra-
tion was measured using BCA Protein Assay Kit (Pierce,
Rockford, IL, USA). Proteins (15μg) were loaded and
separated in NuPAGE Novex 10% Bis-Tris Gel (Invitrogen,
Carlsbad, CA, USA) and transferred to polyvinylidene
difluoride membrane (Millipore, Bedford, MA, USA).
The membrane was immersed in blocking buffer (0.05%
Tween-20 and 3% non-fat milk in phosphate buffered saline)
on a shaker at room temperature for 1 hr, followed by
incubation in primary antibody at 4°C overnight. After
washing with phosphate buffered saline containing 0.05%
Tween-20 for 3 times, the membrane was incubated with
secondary antibody at room temperature for 1 hr and
then washed.
The membrane was visualized by using WesternBright
ECL HRP Substrate (Advansta, Menlo Park, CA, USA) and
captured in a c600 fluorescence and chemiluminescence
imager (Azure Biosystems, Dublin, CA, USA). The primary
antibodies for ETA (ab117521, 1 : 2000), ETB (ab117529,
1 : 2000), phospho-NF-κB p65 (ab86299, 1 : 2000), NF-κB
p65 (ab16502, 1 : 2000), and the reference (internal control)
β-actin (ab8226, 1 : 5000) were purchased from Abcam
(Cambridge, UK). Horseradish peroxidase-conjugated sec-
ondary antibodies (goat anti-mouse, A16078, 1 : 10000;
goat anti-rabbit, A16110, 1 : 10000) were from Invitrogen
(Carlsbad, CA, USA). The experiments were repeated 3 times
independently.
2.6. Enzyme-Linked Immunosorbent Assay (ELISA). A
solid-phase sandwich ELISA kit for rat TNF-α (Invitrogen,
Camarillo, CA,USA)was used to determine the serumTNF-α
level in rats, following the manufacturer’s instructions.
2.7. Statistical Analysis. All data are expressed as mean ±
standard deviation (SD). The vasoconstrictions are presented
as the percentage of response to 60mMK+. The relative
mRNA expression of ETR is presented as a fold change of
control (NS) group, normalized with the mRNA expression
of housekeeping gene EF-1. All data passed normality tests
(α = 0:05). Unpaired Student’s t-test was used for compari-
sons of two data sets. Two-way analysis of variance with
Bonferroni post-test was used for comparisons of series
(functional) data. A P value less than 0.05 was considered
to be significant.
3. Results
3.1. ETR-Mediated Vasoconstriction of Mesenteric Arteries
Was Enhanced by LPS Treatment. To study the vasoconstric-
tion mediated by ETR subtypes, arteries were mounted to a
myograph system, and selective ETR agonists were cumula-
tively added to the organ bath. CRCs mediated by ETB
(S6c) and ETA (ET-1 following desensitization of ETB) were
potently elevated after LPS injection to rats, with increased
maximum effects (EMax) of the agonists (Figure 1). The calcu-
lated pEC50 values (NS versus LPS) were S6c 9:027 ± 0:08561
versus 8:106 ± 0:1287 and ET-1 8:299 ± 0:1457 versus
8:299 ± 0:137, respectively.
3.2. ETR Expression in VSMC Was Augmented by LPS
Treatment. To evaluate the mRNA and protein expression
of ETA and ETB in the VSMC in mesenteric arteries,
QRT-PCR, immunohistochemistry, and Western blot were
performed. Compared to that in the control (NS) group,
LPS treatment remarkably induced both the mRNA
(Figure 2, P < 0:05) and the protein (Figure 3, P < 0:0001;
Figures 4(a)–4(c), P < 0:001) expression of ETA and ETB
in the VSMC.
3.3. LPS Treatment Activated the NF-κB Pathway in the
VSMC. The phosphorylation of NF-κB p65, the key enzyme
of the NF-κB pathway, was detected by using Western blot.
LPS treatment significantly enhanced the phosphorylation
of NF-κB p65 (phospho/total p65, Figures 4(a) and 4(d),
P < 0:01), indicating the activation of the NF-κB pathway
in the VSMC in rats treated with LPS.
3.4. LPS Treatment Increased Serum TNF-α Level in Rats.
ELISA results showed that, 6 hrs after intraperitoneal
injection of LPS (5mg/kg body weight), the serum level
of TNF-α was significantly increased in rats (Figure 4(e),
P < 0:0001), indicating an immediate systemic inflammatory
response in the animals.
4. Discussion
Vital roles of ETRs in embryo development have been dem-
onstrated by abundant studies, for instance, ETB gene null
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Figure 1: Functional assay (myograph) experiments showed enhanced CRCs of vasoconstriction mediated by (a) ETB and (C) ETA and
increased EMax of agonists for (b) ETB and (d) ETA in VSMC of mesenteric arteries in rats received LPS (5mg/kg body weight) injection
for 6 hrs. Data are expressed as mean ± SD. Two-way ANOVA with Bonferroni post-test (CRC) or unpaired Student’s t-test (EMax),
∗P < 0:05, ∗∗P < 0:01, ∗∗∗P < 0:001, ∗∗∗∗P < 0:0001 versus NS, n = 6 (NS) or 4 (LPS) animals for each data point.
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Figure 2: Induction of (a) ETA and (b) ETB mRNA expressions in VSMC in rat mesenteric arteries by LPS injection assessed by real-time
QRT-PCR. Data are expressed as mean ± SD. Unpaired Student’s t-test, ∗P < 0:05 versus NS, n = 5 animals in each group.
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Figure 3: Hematoxylin-eosin staining and immunohistochemical staining on paraffin-embedded tissue sections showed the morphology of
the vessels and the upregulation of ETA and ETB after LPS treatment, respectively. Arteries (without endothelium) were taken from rats
treated with NS or LPS (5mg/kg body weight) for 6 hrs. The arrowhead points to the positive staining of ETA or ETB protein. L: lumen.
The size bar corresponds to 200 μm (150x) or 50μm (600x. (b, c) Semiquantitation of immunohistochemistry results by using ImageJ
software. Data are expressed as mean ± SD. Unpaired Student’s t-test, ∗∗∗∗P < 0:0001 versus NS, n = 10 sections (2 sections per animal) in
each group.
5Mediators of Inflammation
mutation could result in embryonic death in GK rats [13]. In
the vasculature, ETRs are closely linked with many disorders,
particularly in the VSMC. Under pathophysiological condi-
tions, the enhanced ETA and ETB2 expressions in VSMC lead
to dysregulated vascular tone and biological characteristics
that are important for various cardiovascular disorders. The
altered expressions of ETRs have been well-documented in
patients and animal models of cardiocerebrovascular dis-
eases, such as subarachnoid hemorrhage [14, 15], ischemic
stroke [16, 17], and hypertension [18, 19]. Functional assess-
ment revealed enhanced vasoconstriction mediated by ETR,
inducing abnormalities of vascular tone [20]. ETA and ETB
polymorphisms have been demonstrated to be associated
with intracerebral hemorrhage [21].
To understand the association between ETR alteration
and cardiovascular risk factors, for instance, cigarette smok-
ing and dyslipidemia, we established an in vitro organ culture
model and studied the effects of smoking particle extracts
and LDL. It is intriguing to discover that ETA and ETB2
expressions were upregulated by exposure to dimethyl
sulfate-soluble smoking particles [6, 7], or to native LDL
(through lipid peroxidation) [11]. These findings were sup-
ported by the results published by several groups [22, 23].
Various intracellular signals are responsible for the alteration
of ETR, among which, the NF-κB pathway plays a critical
role. For example, the proinflammatory cytokine TNF-α
upregulated ETB2 through activation of NF-κB during organ
culture of rat mesenteric arteries [5]. Whereas inhibition of
NF-κB significantly attenuated the upregulated ETB2 expres-
sion induced by cyclosporin A [24]. The above-mentioned
studies established a fundamental link between risk factors,
inflammation, and upregulation of ETRs in the vasculature.
To further elucidate the regulatory effects of inflamma-
tion on ETR alteration in VSMC in vivo, we intended to
employ an animal model with simple immediate systemic
inflammation. The LPS challenge model was chosen for
the present study. Enhanced ETA levels in renal arteries in
LPS-treated portal hypertensive rats [25] and in cirrhotic rats
[26] were reported. LPS-induced angiogenesis during
chicken embryogenesis could be abolished by combined
ETA and ETB receptor blockade, accompanied by a decrease
in ETA and ETB expressions [27]. Additionally, ETA and
ETB antagonists blocked oroxylin-A-induced vasoconstric-
tion in endotoxemic mesenteric arteries (through intrave-
nous injection of LPS), suggesting alteration of ETR [28]. In
the present study, by intraperitoneal injection of LPS at a
low dose (5mg/kg body weight), we demonstrated not only
the augmented mRNA/protein expressions of ETA and ETB
but also the enhanced ETR-mediated vasoconstriction in
VSMC in rat mesenteric arteries. Despite of the calculated
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Figure 4: (a) Western blot demonstrated enhanced protein expression of ETA and ETB, and phosphorylation of NF-κB p65 in VSMC in
rat mesenteric arteries after LPS injection. The immunoblot of β-actin was used as reference (internal control). (b–d) Semiquantitation
of Western blot results by using ImageJ software. Data are expressed as mean ± SD. Unpaired Student’s t-test, ∗∗P < 0:01, ∗∗∗P < 0:001,
∗∗∗∗P < 0:0001 versus NS, n = 3 animals in each group. (e) Serum TNF-α was increased by LPS (5mg/kg body weight) injection for
6 hrs in rats measured by ELISA. Data are expressed as mean ± SD. Unpaired Student’s t-test, ∗∗∗∗P < 0:0001 versus NS, n = 5
animals in each group.
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pEC50 values that might not be reliable owing to lack of
response to S6c in the NS group, the markedly increased
EMax values indicated the enhanced vasoreactivity to ETR
agonists. This is in concern with a previous finding that intra-
peritoneal injection of a very high dose of LPS (20mg/kg
body weight) for 6 hrs induced pulmonary hypertension in
rats [29]. Intraperitoneal administration of LPS could
increase the TNF-α production by peritoneal macrophages
and hence mediate severe liver damage in pancreatitis rats,
leading to development of multiple organ failure [9, 10]. As
a typical proinflammatory cytokine, TNF-α is known to be
one of the most potent physiological inducers of the intracel-
lular NF-κB pathway [30]. Principally, the binding of a ligand
to a cell surface receptor (like TNF-receptor) results in phos-
phorylation of IKK complex, which phosphorylates IκB and
subsequently leads to its ubiquitination and degradation by
the proteasome, releasing NF-κB to the nucleus to turn on
target genes [31]. NF-κB has been shown to be activated in
all cells, where it regulates expression of diverse target genes
and contributes to the pathogenesis of various diseases [32].
By our data, LPS challenge not only elevated the serum
TNF-α level but also potently augmented ETR-mediated
vasoconstriction and increased ETR mRNA/protein expres-
sions, paralleled with activation of the intracellular NF-κB
pathway in VSMC in the mesenteric arteries. We speculate
that the increased circulating TNF-α could result in activa-
tion of the NF-κB pathway, and this might be at least partly
responsible for the upregulation of ETRs in our model. The
present data provided new insights into the effects of inflam-
mation on the pathophysiological upregulation of ETRs in
VSMC in vivo.
Clinical evaluations on ETR antagonists, including
ambrisentan [33], macitentan [34, 35], and clazosentan [36,
37], confirmed the beneficial effects of ETR antagonism and
further designated the combination of small-molecule epi-
genetic modulators and biologics like monoclonal ETR
antibodies as novel pharmacological therapeutic strategies
[38, 39]. Combining the evidence and clues that the path-
ophysiological upregulation of ETRs induced by inflamma-
tion has been observed under both in vitro and in vivo
conditions, while the clinical application of ETR antagonists
exert ameliorating effects, the alteration of ETRs could be a
promising target in the treatment of cardiovascular disorders
in clinic. Further studies are required to explore the in-depth
mechanisms underlying the abnormalities in ETR expres-
sion, and clinical evaluations with emphasis on the indica-
tions of ETR antagonism in cardiovascular diseases could
be taken into consideration.
5. Conclusion
By using a rat model of LPS-induced immediate systemic
inflammation, we demonstrated the induction of ETA and
ETB expressions at functional, mRNA, and protein levels
in the VSMC in mesenteric arteries. The results provided
new in vivo evidence showing inflammation-induced path-
ophysiological upregulation of ETRs and could be beneficial
for understanding a possible mechanism of inflammation
on exacerbating a vascular tone in the progression of
vascular diseases.
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